35 / 62
Minimum follow-up: 15.8 months;
59 patients (21%) in the nivolumab arm and 40 patients (14%) in the chemotherapy arm were censored
35
Without liver metastases
With liver metastases
OS in Patients Without and With
Baseline Liver Metastases
Nivolumab
(n = 97)
Chemotherapy
(n = 108)
Median OS
3.9
5.9
(95% CI), mo
(2.8–5.6)
(4.6–7.6)
HR (95% CI)
1.34 (0.99–1.80)
Nivolumab
(n = 187)
Chemotherapy
(n = 177)
Median OS
11.2
10.5
(95% CI), mo
(8.2–13.6)
(8.6–11.9)
HR (95% CI)
0.75 (0.59–0.95)
Nivolumab
Chemotherapy
Nivolumab
Chemotherapy
No. at risk
Nivolumab
Chemo
187
177
155
146
118
113
102
95
86
67
68
48
54
33
42
24
36
18
23
9
8
1
1
0
0
0
No. at risk
Nivolumab
Chemo
97
108
54
75
32
48
21
33
13
23
10
14
9
8
7
6
6
4
3
2
1
1
0
0
0
0
Months
Months
OS (%)
100
80
60
40
20
0
0 3 6 9 12 15 18 21 24 27 30 33 36
100
80
60
40
20
0
0 3 6 9 12 15 18 21 24 27 30 33 36
OS (%)